Manages moderately severe acute pain. ANDA 209900, held by Baxter Healthcare. Ketorolac Tromethamine.
As of Nov 21, 2026, ANDA 209900 (Ketorolac Tromethamine), held by Baxter Healthcare, was first approved by FDA on Sep 15, 2017, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Acute Pain in Adult Patients Ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 15, 2017 | Original application | Approved | None posted |
| Ketorolac Tromethamine30MG/ML · injectable;injection | Ketorolac Tromethamine | Rx |
| Ketorolac Tromethamine15MG/ML · injectable;injection | Ketorolac Tromethamine | Rx |
| Nov 21, 2024 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jul 14, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 14, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 28, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 15, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters